Jonathan Janes

Drotrecogin Alfa (Activated) in Adults with Septic Shock

V. Marco Ranieri, Bruce Thompson, Philip S. Barie et al. · New England Journal of Medicine · 2012 · 1.3K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies

Gina A. Montealegre Sanchez, Adam Reinhardt, Suzanne Ramsey et al. · Journal of Clinical Investigation · 2018 · 521 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

Daniel J. Wallace, Richard Furie, Yoshiya Tanaka et al. · The Lancet · 2018 · 513 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +5

Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase<scp>III</scp>trials

Eric L. Simpson, J.‐P. Lacour, Lynda Spelman et al. · British Journal of Dermatology · 2020 · 379 citations

Medicine, Dermatology, Pharmacology +13

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

Jean‐Louis Vincent, Gordon R. Bernard, Richard Beale et al. · Critical Care Medicine · 2005 · 321 citations

Medicine, Pharmacology, Pharmacotherapy +17